In8bio Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is In8bio Inc 's ROA in the second quarter of 2026?
In8bio Inc recorded a cumulative net loss of $-19 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -76.79%.

However, within the Healthcare sector 682 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4182, from total ROA ranking in the first quarter of 2026 at 4904.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	13.16 %	32.19 %	54.13 %	5.03 %	-13.89 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-19	-19	-19	-21	-24
Return On Assets (TTM)	-76.79 %	-80.18 %	-88.07 %	-107.38 %	-125.49 %
INAB's Total Ranking	# 4182	# 4904	# 4408	# 4534	# 4649
Total Assets (TTM) in million	22	26	32	17	19
Seq. Total Assets Change	-16.54 %	-18.64 %	92.52 %	-13.44 %	-2.51 %
Seq. Net Income Change	-	-	-	-	-

INAB's 5 Years Annual ROA >> Back to INAB Management Effectiveness >> Compare INAB ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 101
Sector	# 683
Overall	# 4125

Return On Assets Statistics
High	Average	Low
-7.39 %	-79.08 %	-138.38 %
(Dec 31 2021)		(Mar 31 2025)

News about In8bio Inc Return on Assets ROA

IN8bio's Resolute Focus on INB-100 Ignites Hope for Acute Myeloid Leukemia Patients amid Financial Hurdles,

IN8bio s Strategic Prioritization: Focusing on INB-100 for Acute Myeloid Leukemia amidst Market Challenges
In a recent announcement, IN8bio Inc unveiled its clinical pipeline prioritization strategy, with an emphasis on INB-100, a potential breakthrough therapy for Acute Myeloid Leukemia (AML). As the company aims to address the pressing need for effective treatments in this field, INB shares have reached their lowest point in the past 52 weeks. Furthermore, IN8bio s financial performance during the third quarter of 2023 shows a significant net loss and a negative return on assets (ROA).
The prioritization of INB-100 reflects IN8bio s commitment to advancing innovative solutions for the treatment of AML, a form of cancer that affects the bone marrow, blood, and occasionally other organs. AML poses significant challenges for patients and healthcare providers alike due to its aggressive nature and limited treatment options. INB-100, an investigational cellular therapy, holds promise as a potentially transformative therapy for AML patients, and its prioritization demonstrates IN8bio s commitment to addressing this unmet medical need.
Despite the positive focus on INB-100, IN8bio s latest financial report reveals a cumulative net loss of $-30 million during the twelve months leading up to the third quarter of 2023. This substantial loss further resulted in a negative ROA of -106.4%. These financial challenges have inevitably impacted the company s stock performance, with INB shares hitting their lowest point in the past year.

Financial Statements
In8bio Inc 's Assets	$ 22 million	INAB's Balance sheet
In8bio Inc 's Income	$ -5 million	Quarterly INAB's Income Statement
INAB's Income by Division		See INAB's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	54.13 %	-37.87 %	2.03 %	-21.75 %	-
Total Assets in million	32	21	34	33	42
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-19	-30	-30	-29	-15
Annual Return On Assets	-60.22 %	-145.33 %	-89.02 %	-86.33 %	-34.7 %

INAB's 5 Years Annual ROA >> Back to INAB Management Effectiveness >> Compare INAB ROA to its Competitors

More Return On Assets Ratios
INAB's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
INAB's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for INAB's Competitors
Subscribers only: Roa for In8bio Inc 's Suppliers
Subscribers only: Return On Assets for INAB's Customers

You may also want to know
INAB's Roi	INAB's Inventory Turnover Ratio	INAB's Growth Rates	INAB's Dividend Comparisons
	INAB's Profitability Ratios	INAB's Asset Turnover Ratio	INAB's Dividend Growth
INAB's Roe	INAB's Valuation Ratios	INAB's Financial Strength Ratios	INAB's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T01:18:52+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.